Jade Biosciences, Inc. (JBIO) Stock Price & Analysis
Jade Biosciences, Inc. (JBIO) closed at USD 14.59 on Wednesday, October 28, 2026, down 1.02% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 14.74; the Oct 28, 2026 session ranged USD 14.13–14.9 on volume of 671,339 shares. Market capitalization is $927.89M, with a 52-week range of USD 8.36–28 (NCM). Source: Nexqual, retrieved October 29, 2026 at 06:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/JBIO.md
Key facts (JBIO)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 50.13 (range 40–77).
- Total return with dividends: 1Y +53.7% vs S&P 500 +13.6%; 5Y -97.3% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.79, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (JBIO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$114M | -$165M |
| Net income | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127M | -$153M |
| EPS (diluted) | -$65.45 | -$73.50 | -$100.45 | -$85.40 | -$3.19 | — |
| Free cash flow | -$27.6M | -$39.3M | -$56.9M | — | -$94.9M | — |
| Cash + short-term investments | $167M | $129M | $122M | $78.6M | $336M | — |
| Total debt | — | — | — | $108M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (JBIO)
P/B 2.1x · Earnings yield -16.51%
Analysts (JBIO)
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 50.13 (low 40, high 77).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-27 | BTIG | Reiterated | Buy | $77 |
| 2026-10-01 | Wedbush | Reiterated | Outperform | $47 |
| 2026-10-01 | HC Wainwright & Co. | Reiterated | Buy | $55 |
| 2026-08-11 | Wedbush | Target raised | Outperform | $45 → $47 |
| 2026-08-10 | BTIG | Target raised | Buy | $74 → $77 |
Total return (dividends reinvested) (JBIO)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +53.7% | -97.3% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +54.0% | -51.4% |
| Volatility (annualized) | 71.7% | 169.5% |
| Max drawdown | -50.1% (Apr 2026→Oct 2026) | -99.3% (Mar 2024→Jun 2025) |
JBIO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 10, 2026 | Quarter ended Jun 30, 2026 | −$0.76 | −$0.54 | Miss −40.7% | +1.8% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.57 | −$0.48 | Miss −18.8% | +2.7% |
| Mar 6, 2026 | Quarter ended Dec 31, 2025 | — | — | — | +4.0% |
| Jan 5, 2026 | Quarter ended Sep 30, 2025 | −$0.48 | −$0.67 | Beat +28.4% | -7.0% |
| Nov 14, 2025 | Quarter ended Sep 30, 2025 | −$0.48 | −$0.67 | Beat +28.4% | +30.1% |
| Aug 13, 2025 | — | — | — | — | -8.4% |
| May 14, 2025 | — | — | — | — | -14.1% |
| May 1, 2025 | — | — | — | — | +31.4% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
JBIO recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 28, 2026 | Schedule 13G | Franklin Templeton, Inc., Charles B. Johnson: 6.0% of shares, passive 5%+ holder |
| Oct 27, 2026 | Schedule 13G | BlackRock, Inc.: 5.2% of shares, passive 5%+ holder |
| Sep 30, 2026 | 8-K | Other material event “On September 30, 2026, Jade Biosciences, Inc. ("Jade") announced preclinical data characterizing JADE301, its anti-interferon beta ("IFN- ") monoclonal antibody in development for dermatomyositis ("DM"), a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and progressive muscle weakness. JADE301 is a fully human IgG1 monoclonal antibody with a YTE modification designed to selectively and potently neutralize IFN- and inhibit downstream signaling implicated as a…” |
| Aug 14, 2026 | Schedule 13G/A | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC: 8.3% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | Bellevue Group AG, Bellevue Asset Management AG: 5.0% of shares, passive 5%+ holder (amended) |
| Aug 10, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 10, 2026 | 8-K | Quarterly results |
| Jul 17, 2026 | Schedule 13G | Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 5.1% of shares, passive 5%+ holder |
| Jul 8, 2026 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 10.6% of shares, passive 5%+ holder (amended) |
| Jul 1, 2026 | 8-K | Entered a material agreement “On June 29, 2026, Jade Biosciences, Inc. (the "Company") entered into a License Agreement (the "JADE301 License Agreement") with Paragon Therapeutics, Inc. ("Paragon"), pursuant to which Paragon granted the Company a royalty-bearing, worldwide, exclusive and sublicensable license to use, make, sell, import, export and otherwise exploit certain monospecific antibodies and products targeting an undisclosed target (the "Target") in the field of prophylaxis, palliation, treatment and diagnosis of human disease and…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
JBIO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | JADE301 and Paragon Therapeutics | “From time to time, we can choose to add additional targets by mutual agreement with Paragon and Parade.” |
| Partner | Paragon and Parade Biosciences Holding | “From time to time, we can choose to add additional targets by mutual agreement with Paragon and Parade.” |
| Partner | WuXi Biologics Ireland | “On February 3, 2025, we entered into an amended and restated cell line license agreement (the "Cell Line License Agreement") with WuXi Biologics Ireland Limited ("WuXi Biologics Ireland").” |
Quoted from the company's 10-K filed Mar 6, 2026.
JBIO company outlook (results filed Aug 10, 2026)
- “Interim data are expected in 2027. Jade plans to initiate a registrational Phase 3 clinical trial in the first half of 2027, pending feedback and requirements from the U.S.”
- “Corporate Completed a $172.5 million public offering, extending expected runway into the fourth quarter of 2028. Announced Mark Eisner, M.D., M.P.H., was appointed to the Jade Board of Directors.”
- “Jade's plans to conduct a Phase 3 clinical trial of JADE101, the design and timing thereof and Jade's expectations that such trial will serve as a registrational study;”
- “Jade may use its capital resources sooner than expected; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026).”
Quoted word-for-word from the SEC 8-K results press release.
JBIO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.79 | $0.00 | −$0.79 | $0 | 1 |
| Next quarter (ends Dec 2026) | $-0.81 | $0.00 | −$0.81 | $0 | 1 |
| Current fiscal year (ends Dec 2026) | $-2.93 | $0.00 | −$2.93 | $0 | 1 |
| Next fiscal year (ends Dec 2027) | $-2.66 | $0.00 | −$2.66 | $0 | 1 |
JBIO options: expected move
Options price a move of about ±24.2% (±$3.50) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±12.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 120.5% | ±24.2% |
| Feb 19, 2027 | 114 | 76.2% | ±34.6% |
| May 21, 2027 | 205 | 72.7% | ±43.5% |
30-day implied volatility 78.6% vs 54.5% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 06:26 UTC)
| Price | USD 14.59 |
|---|---|
| Change | ▼ 1.02% (down) |
| Previous Close | USD 14.74 |
| Open | USD 14.57 |
| Day Range | USD 14.13 – 14.9 |
| 52-Week Range | USD 8.36 – 28 |
| Volume | 671,339 shares |
| Market Cap | $927.89M |
| Exchange | NCM |
Technical Analysis (JBIO)
Nexqual's technical model rates JBIO "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 06:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.16 (neutral) |
| vs SMA50 | Below (USD 16.8) |
| MACD | -0.47 (negative) |
Analyst Ratings (JBIO)
Wall Street analysts rate JBIO "Buy" based on 10 analysts, with a mean price target of USD 50.13 (range USD 40–77), per Nexqual as of October 29, 2026 at 06:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 50.13 |
| High Target | USD 77 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (JBIO)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.79 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.76 vs est -0.54 ▼ miss |
| 2026-03-31 | USD -0.57 vs est -0.48 ▼ miss |
| 2025-09-30 | USD -0.48 vs est -0.67 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:26 UTC.
Financials & Fundamentals (JBIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 14.93 |
| Total Cash | $461.20M |
| Total Debt | $1.39M |
Source: Nexqual, October 29, 2026 at 06:26 UTC.
Financial Health Score (JBIO)
Nexqual rates Jade Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $336M cash and investments, no debt (Dec 2025, SEC) |
| Cash Flow | Weak — Operating cash flow -$95M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -35%, ROA -32.5% (last 4 quarters, SEC) |
Ownership (JBIO)
| Insider Ownership | +0.79% |
|---|---|
| Institutional Ownership | +116.16% |
| Shares Outstanding | 63.60M |
| Float | 51.97M |
| Short % of Float | +21.57% |
Source: Nexqual, October 29, 2026 at 06:26 UTC.
Leadership (JBIO)
Jade Biosciences, Inc. is led by Tom Frohlich, President, CEO & Director, per Nexqual as of October 29, 2026 at 06:26 UTC.
| President, CEO & Director | Tom Frohlich |
|---|---|
| CFO & Treasurer | Bradford D. Dahms |
| President of Research & Development | Andrew James King BVMS, D.V.M. |
| Senior Vice President of People | Lori Stewart |
| Senior Vice President of Finance | Jonathan Quick |
Major Backers & Investors (JBIO)
Notable institutional backers of Jade Biosciences, Inc. include FMR, LLC, Jupiter Topco LLC, Fidelity, according to Nexqual as of October 29, 2026 at 06:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.35% |
| Jupiter Topco LLC | 9.86% |
| Fidelity | 7.27% |
| Fairmount Funds Management LLC | 7.16% |
| RA Capital Management, L.P. | 5.77% |
| Venrock Adviser, LLC | 5.06% |
| Bellevue Group AG | 4.81% |
| Paradigm Biocapital Advisors LP | 4.49% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.4% |
Source: Nexqual, October 29, 2026 at 06:26 UTC.
From Jade Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Our approach is to discover and efficiently develop biologics that address emerging targets supported by third-party clinical data and that overcome shortcomings of existing product candidates in development, such as potency, bioavailability, formulation, and pharmacokinetic properties.
Partnerships
- Under the Paragon Option Agreement, we have an exclusive option, on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon (a "License Agreement") that will include an exclusive, worldwide license to all of Paragon's right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies and products directed to the selected target(s) (an "Option").
- In October 2024, we entered into a License Agreement with Paragon (the "JADE101 License Agreement"), pursuant to which Paragon granted us a royalty-bearing, worldwide, exclusive and sublicensable license to use, make, sell, import, export and otherwise exploit certain monospecific antibodies and products targeting APRIL in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the "field").
Legal & Regulatory Risks (Item 1A, quoted)
- We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates.
- Our product candidates for which we intend to seek approval as biologics may face competition from biosimilars sooner than anticipated.
- The FDA's and other regulatory authorities' policies may change and additional government regulations may be promulgated that could prevent, limit or delay marketing authorization of any product candidates we develop.
- We may face difficulties from healthcare and regulatory legislative reform measures.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt